Dermatology

Guest: Eva Parker, MD, FAAD

Rising temperatures, worsening air quality, and extreme weather events appear to be increasing the prevalence and severity of skin diseases. Dr. Eva Parker, Assistant Professor of Dermatology and Core Faculty at the Center for Biomedical Ethics and Society at Vanderbilt University Medical Center, shares strategies for dermatologists to improve climate literacy, reduce their carbon footprint, and educate patients on protecting their skin against climate-related impacts.

Guest: Shari Lipner, MD

Nail psoriasis requires a patient-centric approach that balances targeted treatments with realistic expectations. Dr. Shari Lipner shares expert insights on intralesional steroids, topical therapies, and advanced systemic options to manage this challenging condition. Dr. Lipner is an Associate Professor of Clinical Dermatology and the Director of the Nail Center at Weill Cornell Medicine.

Guest: Shari Lipner, MD

A combination of clinical evaluation, histopathology, and emerging imaging techniques can help diagnose nail psoriasis. Hear from Dr. Shari Lipner, Associate Professor of Clinical Dermatology at Weill Cornell Medicine, as she explains common characteristics of nail psoriasis and best practices for diagnosing it and distinguishing it from similar diseases.

Guest: Atul A. Deodhar, MD, MRCP

Despite feeling some symptom relief with treatment, patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis often experience persistent unmet needs. Residual pain, fatigue, and uncertainty about whether current therapies alter disease progression and outcomes are a few of the challenges that remain unaddressed, emphasizing the need for improved understanding and management of these conditions. Learn about how these difficulties impact patients with Dr. Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics at Oregon Health & Science University.

Guest: Robert Gniadecki, MD

A recent retrospective study using the Alberta Health Services Data Repository of Reporting found that patients with psoriasis had a significantly lower lifespan than a control group of patients with a comparable health profile. Join Dr. Robert Gniadecki, Professor and Director of the Division of Dermatology at the University of Alberta, as he dives into this data and explains implications for clinical practice.

Guest: Robert Gniadecki, MD

For patients with psoriasis, the most effective therapy is not always accessible. Considering patient-specific factors, including overall health, can help create a holistic treatment plan. Tune in to hear from Dr. Robert Gniadecki, Professor and Director of the Division of Dermatology at the University of Alberta, as he discusses best practices for tailoring psoriasis management.

Guest: Andrew Blauvelt, MD, MBA

As the only FDA-designated selective TYK2 inhibitor, deucravacitinib has emerged as a potential therapeutic option for scalp psoriasis. And after analyzing its impacts in a phase III clinical trial, it has continued to show promise in terms of both efficacy and safety. Hear more about deucravacitinib and how it compares to alternate options like JAK inhibitors from Dr. Andrew Blauvelt, a dermatologist and clinical researcher with a focus on innovative treatments for psoriasis.

Guest: Atul A. Deodhar, MD, MRCP

Managing psoriasis, psoriatic arthritis, and axial spondyloarthritis with ixekizumab may cause adverse effects in patients. That’s why a recent research review further investigated the safety of this treatment over time, analyzing data from 25 clinical trials and noting common side effects. Learn more about ixekizumab’s long-term use with Dr. Atul Deodhar, the lead author of this study. He’s also a Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University.

Guest: Philip J. Mease, MD

A recent study led by Dr. Philip J. Mease examined the factors contributing to biologic therapy switching among patients with psoriasis and psoriatic arthritis. Using data from the CorEvitas Psoriasis Registry, the study identified key drivers, including high Psoriasis Area and Severity Index (PASI) scores, poor quality of life, and significant joint pain. Tune in to learn more about these findings and their implications for patient care with Dr. Mease, Director of Rheumatology Research at Providence Swedish Medical Center and Clinical Professor at the University of Washington.

Guest: Daniel M. Klufas, MD

For patients with hidradenitis suppurativa, treatment varies by stage. Topicals, antibiotics, biologics, and procedural interventions can all play a role in management depending on symptoms and severity. Learn more as Dr. Daniel Klufas, an Assistant Professor of Dermatology at the University of California, San Francisco discusses current options and best practices for optimal care.